Trial profile. V indicates bortezomib; M, melphalan; P, prednisone; and T, thalidomide. Four patients in each of the VMP and VTP arms progressed under induction therapy, and 2 patients in the VMP group and 3 in the VTP group progressed just before to start the maintenance phase.